Cleared Traditional

K873282 - CARBAMAZEPINE FPIA FLUORES. POLARIZA. I...

K873282 is the FDA 510(k) clearance for CARBAMAZEPINE FPIA FLUORES. POLARIZA. I... by Windsor Laboratories, Inc.. It is a Class 2 Toxicology device (product code KLT) cleared through the Traditional 510(k) pathway after a 36-day FDA review.

K873282 · Windsor Laboratories, Inc. · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 1987
Decision
36d
Days
Class 2
Risk

K873282 is an FDA 510(k) clearance for the CARBAMAZEPINE FPIA FLUORES. POLARIZA. IMMUNOASSAY. Classified as Enzyme Immunoassay, Carbamazepine (product code KLT), Class II - Special Controls.

Submitted by Windsor Laboratories, Inc. (Garland, US). The FDA issued a Cleared decision on September 22, 1987 after a review of 36 days - a notably fast clearance cycle.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3645 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Windsor Laboratories, Inc. devices

Submission Details

510(k) Number K873282 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 17, 1987
Decision Date September 22, 1987
Days to Decision 36 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
51d faster than avg
Panel avg: 87d · This submission: 36d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code KLT Enzyme Immunoassay, Carbamazepine
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3645
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - KLT Enzyme Immunoassay, Carbamazepine

All 43
Devices cleared under the same product code (KLT) and FDA review panel - the closest regulatory comparables to K873282.
EMIT CONVENIENCE PACK: CARBAMAZEPINE ASSAY
K897114 · Syva Co. · Jan 1990
OPUS CARBAMAZEPINE TEST SYSTEM
K896860 · Pb Diagnostic Systems, Inc. · Jan 1990
EMIT QST CARBAMAZEPINE ASSAY
K882961 · Syva Co. · Aug 1988
ACCULEVEL CARBAMAZEPINE TEST
K871254 · Syva Co. · Jun 1987
EMIT CARBAMAZEPINE ASSAY
K871306 · Syva Co. · Apr 1987
SERALYZER ARIS CARBAMAZEPINE STRIPS/MODU/CALI/CONT
K863842 · Miles Laboratories, Inc. · Jan 1987